Co-Enzyme Q10 for Primary Prevention of CVD: Do Studies Support It?
the MPR take:
Previous research has suggested that co-enzyme Q10 (also known as ubiquinone) deficiency is linked to cardiovascular disease (CVD), but it is not known if the deficiency has a causal effect on CVD or if it is a product of the disease. Most studies have examined the role of CoQ10 for secondary prevention of CVD but not the effect on primary prevention. A review in the Cochrane Library examined six randomized controlled trials of 218 adults ≥18 years of age from the general population and at high risk for CVD on the use of CoQ10 and primary CVD. Four of the studies included patients on statin therapy and two on CoQ10 supplementation alone. In three of the four statin therapy trials, CoQ10 did not significantly influence lipid levels or systolic blood pressure levels; the fourth one presented data in a way that made it difficult to determine if there were significant differences between the CoQ10 only and placebo arms. In the supplementation only studies, one showed evidence of a reduction in systolic blood pressure but no effect on diastolic blood pressure in the pooled analysis of both trials. Because of the small sample sizes in these trials and the high risk of bias, the present results do not support the use of CoQ10 in primary CVD prevention.
Cardiovascular disease (CVD) remains the number one cause of death and disability worldwide and public health interventions focus on modifiable risk factors, such as diet. Coenzyme Q10 (CoQ10) is an antioxidant that is naturally synthesised by the body and can also be taken as a dietary supplement. Studies have shown that a CoQ10 deficiency is associated with cardiovascular disease.